Regenerative heart therapy 'closer' study claims
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A new study in which patients had their hearts repaired with stem cells has brought regenerative treatments for heart attacks a step closer.
The therapy halved the extent of normally permanent scarring on the heart, and led to the growth of new heart muscle.
However, the treatment produced no significant change in “ejection fraction” - a measure of the heart's pumping capacity.
The Caduceus trial recruited a total of 25 patients with an average age of 53 who had all suffered a heart attack in the previous month.
Seventeen received coronary artery infusions of 12 to 25 million stem cells derived from healthy tissue taken from their own hearts. The remaining eight underwent standard post-heart attack care.
A year later, the proportion of the heart left scarred in the stem cell-treated patients had been reduced from 24% to 12%. No change was seen in patients who did not receive the treatment.
Professor Eduardo Marban, director of the Cedars-Sinai Heart Institute in Los Angeles, who led the US team, said: “The effects are substantial, and surprisingly larger in humans than they were in animal tests.
“This discovery challenges the conventional wisdom that, once established, scar is permanent and that, once lost, healthy heart muscle cannot be restored.”
The Phase I study, which was chiefly conducted to evaluate safety, was published today in an online edition of The Lancet medical journal.
It follows a similar trial by US scientists at Harvard Medical School and the University of Louisville whose findings were reported last year, also in The Lancet.
That study, which used a different kind of heart stem cell, produced a 12% average increase in ejection fraction.
Future work will need to see if stem cell treatment can bring any long-term improvement in patients who experience heart failure after a heart attack.
This occurs when a weakened heart is not strong enough to pump sufficient blood around the body, causing breathlessness and exhaustion.
Professor Jeremy Pearson, associate medical director at the British Heart Foundation (BHF), said: “These cells have been proven to form heart muscle in a Petri dish but now they seem to be doing the same thing when injected back into the heart as part of an apparently safe procedure.
“It's early days, and this research will certainly need following up, but it could be great news for heart attack patients who face the debilitating symptoms of heart failure.”
The BHF's Mending Broken Hearts appeal aims to raise £50 million for research into regenerative heart treatments.
PA
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments